Clinical trials: Immunity
Advanced / Metastatic Solid Tumors, Advanced Malignancy
Immunotherapy Master Trial for Advanced Cancers
Over the past decade, cancer immunotherapy has profoundly transformed oncology by harnessing the patient's immune system to target tumors.
- Trial name
- METAREM (NCT07431073)
- Testing
- METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each
- Where
- France
- Volunteers
- 275 people
- Sponsor
- UNICANCER
Carotid Atherosclerosis, Cerebrovascular Accident
Potential Risk Factors for Stroke
Early studies have shown that the immune system may play a role in the development of strokes. Conditions such as high blood pressure, high cholesterol, diabetes, and old age can activate the immune system and increase the risk…
- Conditions
- Carotid Atherosclerosis, Cerebrovascular Accident, Diabetes Mellitus, Hypercholesterolemia
- Trial name
- NCT00001368
- Testing
- cytokine and leukocyte activation profile
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
History of Covid-19, Seroprevalence
Immune Status SARS-CoV-2 in a Sample of a Tertiary Eye Health Centre
A sequential combination of different antibodies test against SARS-CoV-2 is evaluated. The protocol included a rapid test and several ELISA tests within a defined cohort of healthcare workers.
- Trial name
- CovidImmunEye (NCT04446338)
- Testing
- Antibody Test
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Anxiety, Depression - Major Depressive Disorder
Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections: Translating Epidemiology to Deep-phenotyping.
The study protocol was submitted to ERA-NET NEURON for funding on 28/06/2023. Description of the Israeli responsibilities was extracted from the full submitted research protocol. The protocol includes two studies (CHS1 and CHS2).
- Conditions
- Anxiety, Depression - Major Depressive Disorder, Bipolar, Schizophenia Disorder
- Trial name
- Viral-MI (NCT07453420)
- Where
- Israel
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Shalvata Mental Health Center
Malaria
Age of Exposure and Immunity to Malaria in Infants
The overall objective is to evaluate the effect of exposure to Plasmodium (P.) falciparum erythrocytic stage antigens during different periods of infancy on the development of naturally acquired immunity (NAI).
- Trial name
- NCT00231452
- Testing
- Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)
- Where
- Mozambique
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Primary Immunodeficiency Diseases (PID)
Inbon Errors of Immunity Attending Assiut University Children&Amp;#39;s Hospital: a Single Center Study
Aim of Study The aim of this study to describe the clinical profile of children diagnosed as IEIs who were admitted to in Assiut university children\'s Hospital.
- Trial name
- NCT06649643
- Testing
- Inborn errors of immunity, A. Routine .1CBC with blood film. .2Liver Function Test. .3Kidney Function Test. 4. Inflamatory marker ESR, CRP B.Immunology 1-Immunoglobulins IgG, IgM, IgA, IgE 2-Flow cytometric assessment: B
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
HIV Infections
Immune Response to Influenza Vaccine in HIV-Infected Individuals
This study will evaluate how HIV infection, including CD4 cell count and viral load, affects the patient's ability to produce antibodies in response to vaccination with the influenza (flu) vaccine.
- Trial name
- NCT00069914
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever With Warning Signs
Phase 3b Trial To Evaluate Safety And Immune Response (Superiority) of a Two-Dose Butantan-DV Regimen And The Standard Single Dose In Dengue-Naive Children/Adolescents and Immune Response (Non-inferiority) in a Manufacturing Facility Change (DEN-06-IB)
This randomized, double-blind, three parallel-group, multicenter, phase 3b trial evaluates the safety and immunogenicity of Butantan-DV. The study compares two primary immunization regimens (Butantan-DV/Butantan-DV vs.
- Trial name
- DEN-06-IB (NCT07712926)
- Testing
- Butantan-DV (IB), Butantan-DV (WuXi)
- Volunteers
- 1,765 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Hand, Foot and Mouth Disease
Immunogenicity and Safety of Two Different Commercial EV71 Vaccines
The purpose of this study is to evaluate the immunogenicity and safety of sequential vaccination of two EV71 inactived vaccines in healthy infants aged 6-35 months.
- Trial name
- NCT03873740
- Testing
- EV71 inactived vaccine（Vero cells）, EV71 inactived vaccine（Human diploid cells）
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Nosocomial Infection
Healthcare-Associated Infections in Ukraine and the Activity of 4-Thiazolidinone Derivatives Against Related Pathogens
The goal of this observational study is to evaluate the species spectrum and biological properties of bacterial and fungal pathogens causing healthcare-associated infections (HAIs) and to investigate the antimicrobial activity of…
- Trial name
- HAIsUA (NCT06508398)
- Testing
- Microbiological Diagnostic Testing
- Where
- Ukraine
- Volunteers
- 250 people
- Sponsor
- Danylo Halytsky Lviv National Medical University
Malaria
Innate and Acquired Resistance to Plasmodium Falciparum Malaria in Mali
This study, sponsored by NIAID and the University of Bamako, Mali, will identify genetic and other factors that may protect against severe malaria in some children.
- Trial name
- NCT00669084
- Where
- Mali
- Volunteers
- 1,718 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vaccine
Safety and Immune Response of a Rabies Vaccine With the Essen Schedule and a Two-Dose Booster
Rabies is caused by rabies virus with a 100% mortality rate in humans. Most of cases occur in Africa and Asia, mainly in underserved populations. Rabies is a vaccine-preventable disease in both humans and animals.
- Trial name
- NCT07672626
- Testing
- the tested vaccine, the control vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Lung Diseases
Investigating Novel Strategies in Pediatric Immune Responses and Microbiome Environment: Comprehensive Lung Disease Investigation in Children.
The INSPIRE CHILD-study is a clinical research project focused on understanding lung diseases in children. The study aims to explore how the presence of certain bacteria, immune responses, and inflammatory markers in the lungs…
- Trial name
- INSPIRE CHILD (NCT06746077)
- Testing
- No intervention
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Aarhus University Hospital
Acute Tonsillitis
Bacteriophage Therapy in Tonsillitis
The patients received bacteriophage therapy with a liquid piobacteriophage complex (liquid pyobacteriophage complex - PCL). PСL was administered via nebulizer inhalation to irrigate the tonsil mucosa.
- Trial name
- NCT04682964
- Testing
- Nebulizer inhalation irrigation of the mucous membranes of the tonsils with a bacteriophage.
- Where
- Uzbekistan
- Volunteers
- 128 people
- Sponsor
- Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan
Impact of Vaccination
Intranasal LAIV Mucosal Immunity Examination
The research of the investigators is focused on the understanding how the immune system functions and responds to intranasal vaccines.
- Trial name
- NCT07093281
- Testing
- Live Attenuated Influenza Vaccine
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Pneumococcal Infections
A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine
This an open phase Ⅳ clinical trial of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd.The purpose of this study is to evaluate the immunity persistence after single dose of 23-valent…
- Trial name
- NCT04989465
- Testing
- Investigational 23-valent PPV, Control 23-valent PPV
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Recurrent Melanoma, Stage IA Melanoma
Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
This randomized pilot phase II trial studies how well vaccine therapy works in treating human leukocyte antigen class 1 histocompatibility, A-2 (HLA-A2) positive patients with melanoma.
- Conditions
- Recurrent Melanoma, Stage IA Melanoma, Stage IB Melanoma, Stage IIA Melanoma
- Trial name
- NCT00003895
- Testing
- HPV 16 E7:12-20, gp100:209-217(210M), laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Eosinophilic Esophagitis
Innate Immunity in Eosinophilic Esophagitis
The main aim of this study is to assess the expression of innate lymphoid cells in the esophageal mucosa of children with eosinophilic esophagitis (EoE) and in control subjects
- Trial name
- CLOE (NCT03640975)
- Testing
- Endoscopy
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Melanoma
Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma
This study is being done to see if the investigators can help the immune system to work against melanoma. A dendritic cell is another type of white blood cell.
- Trial name
- NCT01456104
- Testing
- Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malaria
Modifying Immunity in Children With DihydROartemisinin-Piperaquine (MIC-DroP)
The MIC-DroP trial will test the hypothesis that preventing early life blood-stage malaria antigenic exposure with intermittent preventive therapy (IPT) enhances protective immunity to malaria.
- Trial name
- MIC-DroP (NCT04978272)
- Testing
- Dihydroartemisinin-piperaquine (DP)
- Where
- Uganda
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Grant Dorsey, M.D, Ph.D.